Skip to content

Ascend Advanced Therapies

Quality manu­fac­turing capacity for developers of gene and cell therapies

First Investment: 2023

Biotech and phar­ma­ceu­tical companies developing innovative gene and cell therapies no longer need to build an in-house capacity to manufacture these therapies. Ascend offers flexible chemistry, manu­fac­turing, and controls (CMC) services for companies working in gene therapy, with an initial focus on Adeno-associated virus (AAV) vectors.

Explore Companies